Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year

1994

Stage

Take Private | Alive

Total Raised

$13.15M

About ZymeTx

ZymeTx is a biotechnology company that engages in the development of products for the diagnosis and treatment of viral disease, viral management, and disease surveillance. ViraZyme, its core technology, exploits the subtle structural differences and characteristics of enzymes to create products to diagnose and treat viruses. The company's diagnostic technology is a platform for proprietary two-part compounds that will split when the compound contacts a specific enzyme, which is the viral target site.

ZymeTx Headquarters Location

800 Research Parkway Suite 100

Oklahoma City, Oklahoma, 73104,

United States

405-271-1314

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

  • When was ZymeTx founded?

    ZymeTx was founded in 1994.

  • Where is ZymeTx's headquarters?

    ZymeTx's headquarters is located at 800 Research Parkway, Oklahoma City.

  • What is ZymeTx's latest funding round?

    ZymeTx's latest funding round is Take Private.

  • How much did ZymeTx raise?

    ZymeTx raised a total of $13.15M.

  • Who are the investors of ZymeTx?

    Investors of ZymeTx include ZymeTx.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.